Company
Noxopharm Ltd
ASX:NOX
Noxopharm Limited is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
93 stories · page 2 of 5
Noxopharm enrols final patient cohort for CEP-2 sarcoma trial after clearing second safety milestone
After recently passing the first safety milestone in August, the CEP-2 trial has passed its second safety milestone and we are now able to escalate to the highest dose of Veyonda ever trialled in cancer patients,” CEO Dr Gisela Mautner said
Noxopharm boosts cash position with $5.011 million R&D rebate
“This rebate strengthens our cash position at a time of critical research activity to advance our drug development pipeline,” said CEO Dr Gisela Mautner.
Noxopharm delivers “promising” results from novel pancreatic cancer study
“What makes this study so exciting is that it is the closest you can get to studying human cancer in the laboratory before giving the drug to patients,” says CEO Dr Gisela Mautner.
Noxopharm and UNSW to present pancreatic cancer research at leading US oncology conference
“It is very encouraging to have this abstract accepted by such a prestigious US conference, as it helps raise the international profile of Noxopharm and UNSW, demonstrates the value of the explant model, and shows the potential of our pre-c
Noxopharm CEP-2 sarcoma trial passes Safety Steering Committee milestone
“We appreciate the contributions the eminent clinicians at our trial sites are making towards our goal of developing an effective treatment for this often-fatal group of cancers,” Noxopharm CEO Dr Gisela Mautner said.
Noxopharm given safety committee green light to increase dose in cancer trial; Hungarian site joins up
The DARRT-2 trial of the company’s asset Veyonda® in a combination treatment for prostate, breast and lung cancer has gained momentum with a safety milestone reached and a European trial site added.
Noxopharm lauds participation of Mayo Clinic and Washington University in CEP-2 Sarcoma trial
With the addition of Mayo Clinic and Washington University, Noxopharm has attracted four leading cancer research institutions in the US to participate in its sarcoma trial, assessing the efficacy of Veyonda and doxorubicin in improving outc